Welcome back to SavvyMonk, your one-stop for AI and tech news that actually matters.

Today we're covering something a little different from the usual software and AI stories. A startup called Loyal is trying to get FDA approval for a drug that slows biological aging in dogs. And they're closer than most people realize.

Let's get into it.

If you’re a decision maker at your company, you need to be on the bleeding edge of, well, everything. But before you go signing up for seminars, conferences, lunch ‘n learns, and all that jazz, just know there’s a far better (and simpler) way: Subscribing to The Deep View.

This daily newsletter condenses everything you need to know about the latest and greatest AI developments into a 5-minute read. Squeeze it into your morning coffee break and before you know it, you’ll be an expert too.

Subscribe right here. It’s totally free, wildly informative, and trusted by 600,000+ readers at Google, Meta, Microsoft, and beyond.

Loyal is a San Francisco biotech founded in 2019 by Celine Halioua, and the company has one goal: get the first FDA-approved drug for lifespan extension in any species. Not humans. Dogs.

The thinking is that dogs age faster, trials run shorter, and the science of canine aging is actually well-understood. If you can prove it works in dogs, you've cracked something fundamental about biological aging.

The drug they're furthest along with is LOY-002, a daily prescription pill targeting age-related metabolic dysfunction. It's designed for dogs 10 years and older weighing at least 14 lbs.

The drug works as a caloric restriction mimetic, meaning it delivers some of the longevity benefits associated with caloric restriction without requiring the animal to actually eat less or lose weight. In plain terms, it's trying to make an old dog's metabolism behave more like a younger dog's.

Where Things Stand

FDA approval for a new animal drug requires clearing three major technical sections. As of January 2026, Loyal has cleared two.

The FDA's Center for Veterinary Medicine accepted the safety package (called Target Animal Safety, or TAS) for LOY-002 in December 2025, following the efficacy acceptance it received in February 2025. The safety submission included data from multiple studies and over 400 dogs enrolled in Loyal's clinical trial.

The third and final section is manufacturing, which Loyal is currently working through. The company expects to submit that section and apply for Expanded Conditional Approval (XCA) in 2027. Full approval would follow after the completion of the STAY study, Loyal's pivotal efficacy trial.

The STAY Study

The STAY study is the clinical backbone of LOY-002's approval path. Loyal enrolled 1,300 senior dogs across 70 veterinary clinics in the US, completing enrollment in July 2025. That makes it the largest clinical trial in veterinary medicine history. Half the dogs receive LOY-002, half receive a placebo. The trial is expected to run four years, meaning full data won't be available until at least 2027.

Halioua said in a statement when the safety acceptance was announced: "Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension. This safety acceptance brings us very close to achieving that vision."

The Science Behind It

Metabolic health declines in all dogs as they age, even generally healthy ones. That decline is tied to a higher burden of disease and a worse quality of life in senior years. LOY-002 targets those metabolic drivers before the damage accumulates. The idea is to extend healthspan, the period when a dog is actually healthy and active, rather than just adding time at the end when they're already suffering.

Research on caloric restriction in dogs supports the concept. Studies have shown that calorie-restricted dogs lived roughly two years longer than controls and had delayed onset of cancer and osteoarthritis. LOY-002 tries to capture those benefits pharmacologically. The safety study tested doses at 1x, 3x, and 5x strength with no clinically significant adverse events.

The Bigger Picture

Loyal has raised over $150 million since founding, including a $22 million B-2 round closed in early 2025. The company has two other drugs in development alongside LOY-002. LOY-001 targets large and giant breed dogs by reducing excess IGF-1, a hormone linked to shorter lifespans in bigger dogs. LOY-003 is for dogs five years and older weighing at least 60 lbs.

If any of these reach approval, it would mark the first time a regulatory agency anywhere in the world has cleared a drug explicitly for lifespan extension. That's not a small thing. The science and the regulatory pathway being built here could eventually inform how similar approaches are pursued in humans.

The Bottom Line

LOY-002 is not approved yet, and 2026 is not a realistic launch window at this point regardless of what earlier timelines suggested. The manufacturing review and XCA application are expected in 2027. But two of three major FDA hurdles are cleared, the safety data looks clean, and the clinical trial is the largest in veterinary history.

Loyal has been methodical about this, and they're building something that has never existed before. If it works, your vet might one day prescribe a daily pill that buys your dog a couple more healthy years. That's genuinely worth watching.

Category: Research Summarization

"Summarize the current state of [scientific or regulatory topic] as if explaining it to someone smart but completely unfamiliar with the field. Cover what the goal is, where things stand today, what obstacles remain, and what success would mean. Keep it under 300 words and avoid jargon."

The dog longevity space sounds niche, but what Loyal is actually doing is building the first regulatory framework for an aging drug anywhere in the world. The FDA doesn't have a category for "drugs that slow aging." Loyal is creating it. Whatever happens with LOY-002, that precedent matters far beyond dogs.

Hit reply, I read every response.

See you in the next one.

— Vivek

P.S. Know someone who would enjoy straight-talk tech and AI coverage? Send this their way. They can subscribe at https://savvymonk.beehiiv.com/